Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01231971 · ClinicalTrials.gov registry record
Alzheimer's Disease Neuroimaging Initiative 2
A clinical trial of Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), sponsored by University of Southern California.
- Completed
- Registry status
- 1,182
- Enrollment target
- 20
- Study locations
NCT01231971: Completed study of Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), sponsored by University of Southern California.
NCT01231971 is a study of Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD) that has completed, run by University of Southern California. The registered enrollment target is 1,182 participants, above the 97-participant average among 19 other Mild Cognitive Impairment (MCI) trials with a reported enrollment target (1119% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01231971, a study of Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- 1,182 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1) and ADNI-GO (Grand Opportunity; a study funded through an NIH grant under the American Recovery and Reinvestment Act), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI2 seeks to inform the neuroscience of AD. This information will aid in the early detection of AD, and in measuring the effectiveness of treatments in future clinical trials.
Conditions Studied
Interventions
- DRUG Flortaucipir
- DRUG Florbetapir
Study Locations (20)
California
- University of California, Irvine - Irvine
- University of California, San Diego - La Jolla
- University of Southern California - Los Angeles
- University of California, Los Angeles - Los Angeles
- University of California, Davis - Martinez
- University of California, Irvine (Brain Imaging Center) - Orange
- Stanford University / PAIRE - Palo Alto
- University of California, San Francisco - San Francisco
Florida
- Mayo Clinic, Jacksonville - Jacksonville
- Wien Center for Clinical Research - Miami Beach
- USF Health Byrd Alzheimer's Institute - Tampa
- Premiere Research Institute - West Palm Beach
Arizona
- Banner Alzheimer's Institute - Phoenix
- Banner Sun Health Research Institute - Sun City
District of Columbia
- Georgetown University - Washington D.C.
- Howard University - Washington D.C.
Alabama
- University of Alabama, Birmingham - Birmingham
Connecticut
- Yale University School of Medicine - New Haven
Georgia
- Emory University - Atlanta
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,182 participants |
| Start Date | 2011-02-14 |
| Est. Completion | 2017-11-29 |
What the finished NCT01231971 record still lists
NCT01231971 is an observational study that tracks outcomes without assigning an intervention. Its 1,182 participants enrollment target places it among the larger protocols in the corpus, above the 97-participant average among 19 other Mild Cognitive Impairment (MCI) trials with a reported enrollment target (1119% higher).
The record links to 5 conditions, with Mild Cognitive Impairment (MCI) appearing as the primary indexed condition, and to 2 interventions - of which Flortaucipir is the first listed.
NCT01231971 names 20 study sites across 8 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT01231971 about?
NCT01231971 is a clinical study titled "Alzheimer's Disease Neuroimaging Initiative 2". The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1) and ADNI-GO (Grand Opportunity; a study funded through an NIH grant under the American Recovery and Reinvestment Act), to examine how brain imaging technology can b...
What is the current status of trial NCT01231971?
This trial is currently completed. The enrollment target is 1,182 participants. The study started on 2011-02-14. Estimated completion is 2017-11-29.
What conditions does trial NCT01231971 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI).
What interventions are being tested in trial NCT01231971?
The interventions under investigation include: Flortaucipir (DRUG), Florbetapir (DRUG).
Who is sponsoring clinical trial NCT01231971?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01231971 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment (MCI)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01231971's enrollment target sits among peer trials
1,182 1st of 19 higher than 19 of 19 other Mild Cognitive Impairment (MCI) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment (MCI) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Music for the Mind Study
RECRUITING · NA
-
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
RECRUITING · NA
-
The "Let's Talk Tech" Tool to Support Decision Making About Technology Use
RECRUITING · NA
-
Project Gnosis: the Neurophysical and Psychosocial Health Outcomes of Tai Chi for Older Adults with Cognitive Concerns or Mild Cognitive Impairment
RECRUITING · NA
-
Working Memory Training in Patients with Mild Cognitive Impairment
RECRUITING · NA
-
Treating Insomnia in Mild Cognitive Impairment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- NCT05688436 · 1,178 participants
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- NCT06931275 · 1,178 participants · NA
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI